Sonja Zweegman Selected Research

ixazomib

9/2023	Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.
9/2023	Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13.
1/2021	Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
1/2021	Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.
12/2020	Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.
11/2020	Ixazomib Treatment of IgA Multiple Myeloma With Hyperviscosity Syndrome.
1/2019	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
12/2018	Ixazomib for the treatment of multiple myeloma.
1/2018	Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
9/2017	Elderly patients with multiple myeloma: towards a frailty approach?

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sonja Zweegman Research Topics

Disease

109	Multiple Myeloma 04/2024 - 07/2005
34	Neoplasms (Cancer) 04/2024 - 11/2012
12	Leukemia 01/2021 - 10/2007
11	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 10/2010
10	Infections 12/2023 - 05/2013
8	Primary Myelofibrosis (Myelosclerosis) 01/2023 - 11/2012
7	Hematologic Neoplasms (Hematological Malignancy) 06/2022 - 10/2010
6	Disease Progression 12/2021 - 01/2014
5	Residual Neoplasm 11/2021 - 09/2005
5	Thrombocytopenia (Thrombopenia) 10/2019 - 10/2010
4	COVID-19 01/2023 - 01/2020
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2021 - 12/2013
4	Chromosome Aberrations (Chromosome Abnormalities) 01/2021 - 01/2016
3	Cytokine Release Syndrome 01/2023 - 11/2020
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023 - 07/2002
3	Lymphoma (Lymphomas) 01/2022 - 04/2016
3	Frailty 01/2022 - 09/2017
3	Bone Diseases (Bone Disease) 01/2021 - 04/2012
3	Plasmacytoma 06/2020 - 01/2011
3	Amyloidosis 11/2019 - 05/2013
3	Essential Thrombocythemia 01/2016 - 11/2012
3	Renal Insufficiency (Renal Failure) 11/2014 - 01/2005
2	Polyneuropathies (Polyneuropathy) 09/2023 - 01/2015
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2022 - 01/2022
2	Fever (Fevers) 08/2022 - 01/2011
2	Septic Shock (Toxic Shock Syndrome) 08/2022 - 10/2021
2	Neutropenia 08/2022 - 10/2021
2	Testicular Neoplasms (Testicular Cancer) 01/2022 - 10/2010
2	Pain (Aches) 01/2021 - 12/2020
2	Inflammation (Inflammations) 12/2019 - 07/2005
2	Anemia 12/2017 - 10/2015
2	Hemorrhage 01/2017 - 01/2016
2	Thrombosis (Thrombus) 01/2017 - 01/2016
2	Splenomegaly 01/2016 - 08/2013
2	Venous Thrombosis (Deep-Vein Thrombosis) 01/2016 - 12/2002
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 02/2015 - 01/2014
2	Polycythemia Vera 07/2014 - 11/2012
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 06/2014 - 01/2013

Drug/Important Bio-Agent (IBA)

28	Bortezomib (Velcade)FDA Link 10/2021 - 07/2005
25	Dexamethasone (Maxidex)FDA LinkGeneric 09/2023 - 12/2006
22	daratumumabIBA 10/2023 - 01/2016
21	Thalidomide (Thalomid)FDA Link 09/2023 - 01/2008
17	Lenalidomide (CC 5013)FDA Link 10/2022 - 04/2010
17	Proteasome InhibitorsIBA 01/2021 - 01/2013
13	Monoclonal AntibodiesIBA 12/2023 - 05/2013
13	Melphalan (Alkeran)FDA LinkGeneric 01/2022 - 02/2010
12	AntigensIBA 11/2023 - 12/2002
11	Chimeric Antigen ReceptorsIBA 11/2023 - 01/2017
10	ixazomibIBA 09/2023 - 09/2017
8	carfilzomibIBA 10/2022 - 12/2013
8	Proteins (Proteins, Gene)FDA Link 11/2021 - 01/2007
7	Bispecific AntibodiesIBA 04/2024 - 11/2020
7	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 12/2023 - 11/2020
7	ruxolitinibIBA 01/2023 - 07/2017
7	Prednisone (Sone)FDA LinkGeneric 06/2020 - 07/2010
6	CytokinesIBA 04/2024 - 01/2017
6	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2021 - 12/2013
5	fedratinibIBA 01/2022 - 07/2017
4	B-Cell Maturation AntigenIBA 12/2023 - 11/2020
4	AntibodiesIBA 11/2023 - 01/2018
4	pomalidomideIBA 10/2022 - 09/2017
4	Immunoglobulin G (IgG)IBA 01/2022 - 06/2014
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 03/2014
4	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2014
4	Rituximab (Mabthera)FDA Link 01/2017 - 01/2013
3	VaccinesIBA 12/2023 - 12/2021
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 02/2010
3	Immunomodulating AgentsIBA 01/2020 - 09/2017
3	Histone Deacetylase InhibitorsIBA 01/2018 - 07/2014
3	Syntex adjuvant formulationIBA 12/2017 - 11/2012
2	Immunoglobulins (Immunoglobulin)IBA 01/2023 - 01/2020
2	LigandsIBA 01/2023 - 06/2007
2	Antiviral Agents (Antivirals)IBA 01/2023 - 01/2023
2	tocilizumab (atlizumab)FDA Link 01/2023 - 11/2020
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 05/2013
2	2019-nCoV Vaccine mRNA-1273IBA 10/2022 - 01/2022
2	ibrutinibIBA 10/2022 - 01/2022
2	Janus Kinase InhibitorsIBA 01/2022 - 01/2016
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 12/2021 - 01/2014
2	Zoledronic Acid (Zometa)FDA Link 01/2021 - 10/2015
2	EpitopesIBA 01/2021 - 01/2019
2	Complement System Proteins (Complement)IBA 12/2020 - 12/2017
2	Immunoglobulin A (IgA)IBA 11/2020 - 06/2014
2	ADP-ribosyl Cyclase 1IBA 01/2019 - 01/2017
2	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 11/2016
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2017 - 02/2015
2	Hemoglobins (Hemoglobin)IBA 10/2015 - 01/2007
2	Vorinostat FDA Link 07/2014 - 08/2013
2	PR-957IBA 01/2014 - 12/2013

Therapy/Procedure

53	Therapeutics 12/2023 - 01/2008
20	Stem Cell Transplantation 08/2022 - 12/2010
11	Drug Therapy (Chemotherapy) 08/2022 - 09/2005
5	Aftercare (After-Treatment) 10/2023 - 03/2011
4	Duration of Therapy 01/2023 - 03/2014
3	Immunotherapy 11/2023 - 01/2021
3	Transplantation 10/2022 - 01/2013
3	Radiotherapy 01/2021 - 01/2016
2	Cell Transplantation 10/2022 - 01/2022
2	Precision Medicine 01/2021 - 01/2020
2	Erythrocyte Transfusion 12/2017 - 01/2017